Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Ambrx Biopharma Inc. (AMAM)

5.06   -0.28 (-5.24%) 01-21 17:37
Open: 5.3 Pre. Close: 5.34
High: 5.73 Low: 4.9028
Volume: 19,613 Market Cap: 177M
Ambrx Biopharma Inc., a clinical-stage biologics company, focuses on discovering and developing engineered precision biologics using its proprietary expanded genetic code technology platform. Its lead product candidate is ARX788, an anti-HER2 antibody-drug conjugate (ADC), which is investigated in various clinical trials for the treatment of breast cancer, gastric/gastroesophageal junction cancer, and other solid tumors, including ongoing Phase 2/3 clinical trials for the treatment of HER2-positive metastatic breast cancer and gastric cancer. The company is also developing two earlier-stage product candidates, including ARX517, an anti-PSMA ADC, which is in a Phase 1 clinical trial for the treatment of prostate cancer and other solid tumors; and ARX305, an anti-CD70 ADC in investigational new drug-enabling studies for the treatment of renal cell carcinoma and other cancers, as well as other multiple product candidates targeting immuno-oncology applications. In addition, it is developing ARX102, an immuno-oncology IL-2 pathway agonist to stimulate the patient's own immune system by targeting the Ã? and gamma receptors on the cytotoxic T cell; and ARX822, a fab-small molecule bispecific that is in preclinical development for cancers. Ambrx Biopharma Inc. has collaborations with various pharmaceutical companies, which include Bristol Myers Squibb Company; AbbVie Inc.; Astellas Pharma Inc.; and Elanco Animal Health. The company was founded in 2003 and is based in La Jolla, California.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 5.742 - 5.777 5.777 - 5.802
Low: 4.828 - 4.868 4.868 - 4.898
Close: 5.006 - 5.067 5.067 - 5.112

Technical analysis

as of: 2022-01-21 4:24:42 PM
Overall:       
Stoxline posted a STRONG SELL today, downgraded from higher rating. Downward movement to be expected.
Target: Six months: 9.71     One year: 12.17
Support: Support1: 4.90    Support2: 4.08
Resistance: Resistance1: 8.31    Resistance2: 10.42
Pivot: 7.14
Moving Average: MA(5): 5.63     MA(20): 7.62
MA(100): 11.50     MA(250):
MACD: MACD(12,26): -1.12     Signal(9): -0.89
Stochastic oscillator: %K(14,3): 5.54     %D(3): 11.36
RSI: RSI(14): 19.02
52-week: High: 22.87  Low: 4.90  Change(%): -70.3
Average Vol(K): 3-Month: 18  10-Days: 23

Price, moving averages and Bollinger Bands

Price and moving averages has closed below its Short term moving average. Short term moving average is currently below mid-term; AND below long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BEARISH in short-term; and BEARISH in mid-long term.
AMAM has closed above bottom band by 12.4%. Bollinger Bands are 75.6% wider than normal. The large width of the bands suggest high volatility as compared to Ambrx Biopharma Inc.'s normal range. The bands have been in this wide range for 4 bars. This is a sign that the current trend might continue.

Headline News

Tue, 04 Jan 2022
Anebulo Pharmaceuticals Names Biotechnology Industry Executive Simon Allen as CEO and Director - Business Wire

Wed, 29 Dec 2021
Ambrx Biopharma (AMAM) Sees Hammer Chart Pattern: Time to Buy? - Entrepreneur

Thu, 09 Dec 2021
Ambrx Biopharma Stock (AMAM): Why The Price Jumped Today - Pulse 2.0

Mon, 06 Dec 2021
Ambrx Biopharma Inc - ADR Shares Fall 3.6% Below Previous 52-Week Low - Market Mover - Nasdaq

Fri, 19 Nov 2021
Ambrx Biopharma Inc. Announces Acceptance of Two Poster Presentations at the 2021 San Antonio Breast Cancer Symposium - Yahoo Finance

Mon, 01 Nov 2021
Ambrx Biopharma Inc. to Present at the 30th Annual Virtual Credit Suisse Healthcare Conference - Business Wire

Financial Analysis

Growth NA
Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability NA
Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.
Solvency NA
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency NA
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Price to Book Value: Neutral Discounted cash flow: Neutral
Return on Assets: Neutral Price to Earnings: Neutral
Return on Equity: Neutral Debt to Equity: Neutral
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NYSE
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M) 35
Shares Float (M) 14
% Held by Insiders
% Held by Institutions 38.92
Shares Short (K) 3
Shares Short P. Month (K) 3

Stock Financials

EPS -4.970
EPS Est This Year
EPS Est Next Year
Book Value (p.s.) 5.520
Profit Margin
Operating Margin -262.70
Return on Assets (ttm)
Return on Equity (ttm)
Qtrly Rev. Growth -20.8
Gross Profit (p.s.) 0.391
Sales Per Share 0.352
EBITDA (p.s.) -0.870
Qtrly Earnings Growth
Operating Cash Flow (M) -40
Levered Free Cash Flow (M)

Stock Valuations

PE Ratio -1.02
PEG Ratio
Price to Book value 0.92
Price to Sales 14.36
Price to Cash Flow

Stock Dividends

Dividend
Forward Dividend
Dividend Yield
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
7 Binary Options
Your Ad Here
android_stock_chart
Stock Chart
stoxline_lite
Stoxline Lite
stoxline_pro
Stoxline Pro
Option_Calculator
Option Calculator
(c) 2006-2020 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.